Amalgamated Financial’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Amalgamated Financial’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$19K	Buy	+1,670	New	+$17.9K	﹤0.01%	2767

Other funds holding THRX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Amalgamated Financial's THRX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2022: 1,670 shares worth $19K. The stake represents ﹤0.01% of the portfolio and ranks #2767 among its holdings.

47 funds tracked by Wall St. Rank hold THRX as of Q1 2022.

Amalgamated Financial held 1,670 shares of Theseus Pharmaceuticals, Inc. Common Stock worth $19K as of Q1 2022.
Theseus Pharmaceuticals, Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
Theseus Pharmaceuticals, Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2767 holding.
47 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.